Pediatrix Medical Group, Inc. (MD) Form 8-K — Aug 4, 2026
Pediatrix Medical Group reported financial results for the second quarter of 2026, achieving net revenue of $488 million, a 4.0% increase compared to the prior-year period. The company generated net income of $40 million, or $0.49 per diluted share, while Adjusted EBITDA grew to $76 million, driven by favorable reimbursement trends and recent acquisitions. The company demonstrated strong cash generation from continuing operations of $126.3 million and utilized $42.7 million to repurchase shares during the quarter. Pediatrix ended the quarter with $288.9 million in cash and total debt of $584 million, reaffirming its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million.
Key figures
- Eps
- 0.49
- Revenue
- 487.8 million
- Guidance
- $280 million to $300 million
- Net Income
- 39.8 million
- Total Debt
- 584 million
- Revenue Yoy
- 4.0%
- Cash Position
- 288.9 million
- Adjusted EPS
- $0.63
- Adjusted EBITDA
- $76 million
- Share Repurchases
- $42.7 million
- Weighted Average Shares Outstanding
- 81.4 million
Price after filing
Close on the filing date to close N calendar days later (from $26.48). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.